Monoclonal Antibodies

Two Vanderbilt University faculty who conducted translational research have received the distinction of Best Invention of 2022 from TIME magazine.  Read More

The Vanderbilt Vaccine Center will host a campus-wide presentation by Mark Esser, AstraZeneca vice president and head of microbial sciences, about Evusheld, an antibody combination that combats SARS-CoV-2 developed at Vanderbilt University Medical Center. The talk will be on Thursday, Nov. 17, at 10 a.m. in Light Hall, Room 202. Read More

Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization. Read More

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19. Read More

A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States. Read More

The U.S. Food and Drug Administration granted emergency use authorization Dec. 8 to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination that protects against COVID-19, discovered last year at Vanderbilt University Medical Center. Read More

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. Read More

A monoclonal antibody cocktail against the COVID-19 virus discovered at VUMC is the first non-vaccine modified to demonstrate the prevention of COVID-19 in a clinical trial of more than 5,000 participants. The antibody treatment could afford up to 12 months of protection from COVID-19, and preliminary laboratory findings also suggest that it can neutralize the delta variant. Read More

Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature. Read More

Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential. Read More

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development. Read More

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.... Read More

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center. Read More

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections. Read More

James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award. Read More

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. Read More

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection. Read More

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio. Read More

Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months. Read More

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection. Read More